

Phenotypic deconvolution: the next frontier in pharma

Marvin Steijaert (Open Analytics NV) -Vladimir Chupakhin (Janssen Pharmaceutica) -Hugo Ceulemans (Janssen Pharmaceutica) -Joerg Wegner (Janssen Pharmaceutica) -July 2, 2015

About me and Open Analytics NV


- MSc in Biomedical Engineering
- PhD in Systems Biology / Computational Biology
- · Consultant at Open Analytics
- marvin.steijaert@openanalytics.eu



A data scientist's best friend

http://www.openanalytics.eu/architect






Pharma, the simple story


Protein target

Focus on isolated disease related targets



Compound

- Screening for lead compounds
- Further optimization (chemical modification)
- Blockbuster drug







Pharma, the true story

High failure rates in clinical trials






Pharma, the true story

High failure rates in clinical trials


- Phase II success rates below 20%
- 84% of clinical trials fail due to efficacy and safety issues




Arrowsmith, J. & Miller, P. Nat Rev Drug Discov, 2013

Phenotypic assays

- Attempt to reduce failure rates
- · Compounds activity measured in different type of assay
 - Disease-relevant, multi-target, cellular context
 - Instead of classic assay: isolated target





Phenotypic high-content imaging assay




Phenotypic target identification

- Unknown mode of action in phenotypic assay
 - Required for further drug development
- \cdot Task: Identify targets that can best explain compound activity in phenotypic assay







Ensemble of best classifiers




- · Literature in chemogenomics field: only public data
- We use public + internal + commercial data
 - More (and better quality) train data
 - Better prediction quality
- \cdot Not all available methods were up to the task



- How well does a target explain the phenotype?
 - ROC-AUC
- How well do multiple targets explain the phenotype?
 - Elastic net logistic regression (glmnet)
 - Random Forest (Boruta)





Next steps

- Scientific:
 - Ongoing improvements of methods
 - Repeat benchmark with additional sampling
 - Publication(s)
- Operational:
 - Application in various disease areas
 - Now: experimental follow up
 - Iterative cycle of wet lab experiments and modeling







Acknowledgements

Contributors

- \cdot University of Linz
 - Sepp Hochreiter
- University of Leuven
 - Yves Moreau
- \cdot IMEC
 - Roel Wuyts
- Arcadia
- Intel Corporation NV
- Janssen Pharmaceutica
 - R&D Discovery Sciences, Computational Sciences
- Open Analytics

Sponsors

- $\cdot \;$ ChemBioBrige IWT
- Exascience IWT

Tak for din opmærksomhed!

Bonus material

Under the hood...

- **C++** (heavy work on "large matrix")
 - Boost
 - TBB
 - JCompoundMapper
- **Spark** on **YARN** (distributed runs for nested cross-validation)
- **R** (everything else, including analysis and postprocessing)
 - Faster, simpler and more elegant code : data.table
 - Target identification : glmnet, Boruta, randomForest
 - Reporting : rmarkdown